NF-kappaB: a therapeutic target in inflammatory diseases.
The transcription factor NF-kappaB has been implicated in the pathogenesis of a variety of both acute and chronic inflammatory diseases. Many agents have shown promise and potential to abrogate NF-kappaB activity in both in vitro and in vivo systems. These include antioxidants, corticosteroids, proteasome inhibitors, arachadonic acid pathway metabolites, salicylates, molecular interventions and cell-permeable peptides. Unfortunately, therapies aimed at blocking its activation have not proven clinically feasible at this time. As the complex signal transduction pathways leading to NF-kappaB activation are further elucidated, more specific inhibitors of NF-kappaB are likely to be identified.
Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University School of Medicine, and The Department of Veterans Affairs, Nashville, TN, USA.
C L
CL
Curran
T S
TS
Blackwell
J W
JW
Christman